Download Files:
Products Details
Product Description
– Firocoxib-d4 (ML 1785713-d4) is the deuterium labeled Firocoxib. Firocoxib (ML 1785713) is a potent, selective and orally active COX-2 inhibitor with an IC50 of 0.13 μM. Firocoxib shows 58-fold more selective for COX-2 than COX-1 (IC50 of 7.5 μM). Firocoxib has anti-inflammatory effects[1].
Web ID
– HY-14670S
Shipping
– Room temperature
Applications
– COVID-19-immunoregulation
Molecular Formula
– C17H16D4O5S
References
– [1]Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53(2):211-216.|[2]Steagall PV, et al. Evaluation of the adverse effects of oral firocoxib in healthy dogs. J Vet Pharmacol Ther. 2007 Jun;30(3):218-23.|[3]Stock ML, et al. Pharmacokinetics of firocoxib in preweaned calves after oral and intravenous administration. J Vet Pharmacol Ther. 2014 Oct;37(5):457-63.|[4]Albanese F, et al. Clinical outcome and cyclo-oxygenase-2 expression in five dogs with solar dermatitis/actinic keratosis treated with firocoxib. Vet Dermatol. 2013 Dec;24(6):606-12, e147.|[5][1].McCann ME, et al. In vitro effects and in vivo efficacy of a novel cyclooxygenase-2 inhibitor in cats with lipopolysaccharide-induced pyrexia. Am J Vet Res. 2005 Jul;66(7):1278-84.
CAS Number
– 1325700-11-5
Molecular Weight
– 340.43
SMILES
– O(CC1C(C1([2H])[2H])([2H])[2H])C2=C(C(C)(C)OC2=O)C3=CC=C(S(C)(=O)=O)C=C3
Clinical Information
– No Development Reported
Research Area
– Inflammation/Immunology
Solubility
– 10 mM in DMSO
Target
– COX;Isotope-Labeled Compounds
Pathway
– Immunology/Inflammation;Others
Product type
– Isotope-Labeled Compounds
Disclaimer: All products are for Research use only unless clearly stated otherwise on the product datasheet. Datasheets provided on the website are drafts for reference purpose only and you are requested to always refer to the hard copy included in the kit for your experimentation. Agdia Products are available for delivery only in Canada.
